Biodexa Pharmaceuticals (BDRX) EPS (Basic) (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) posted EPS (Basic) of -$0.0 for Q2 2025, down 210.29% sequentially from -$0.0 in Q4 2024.

Biodexa Pharmaceuticals (BDRX) EPS (Basic) (2013 - 2025) Analysis & Trends

Biodexa Pharmaceuticals has reported EPS (Basic) for 13 years, with the latest figure at -$0.0 in Q2 2025.

Quarterly EPS (Basic) changed N/A year-over-year to -$0.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$0.0 (up 55.89% YoY) and the FY2025 annual result came in at -$0.0, down 144.71% from the prior year.
EPS (Basic) declined to -$0.0 in Q2 2025 per BDRX's latest filing, from -$0.0 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.0 in Q4 2024 and troughed at -$2.92 in Q4 2021.
A 5-year average of -$0.6 and a median of -$0.12 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2023: EPS (Basic) soared 44.48% in 2022, then jumped 99.95% in 2023.
Over 5 years, EPS (Basic) stood at -$2.92 in 2021, then jumped by 60.28% to -$1.16 in 2022, then jumped by 99.95% to -$0.0 in 2023, then soared by 44.92% to -$0.0 in 2024, then sank by 210.29% to -$0.0 in 2025.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.0, -$0.0, and -$0.0 for Q2 2025, Q4 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	Biodexa Pharmaceuticals	63,168.17	-11.29 Mn	-	-

Download Data